Introduction
============

There are several pregnancy indices of hormonal changes (such as oestrogens, progesterone, corticotropin-releasing hormone, cortisol, human placental growth hormone and human placental lactogen) that are implicated in the development of gestational diabetes (GDM) cases ([@bib1]). Epidemiological evidence has consistently shown that among mothers with prior history of GDM, 30--84% of them had GDM recurrence in subsequent pregnancies ([@bib2]), 20--40% developed metabolic syndrome (MetS) within 2--20 years ([@bib3], [@bib4]) and 17--63% developed type 2 diabetes mellitus (T2DM) and obesity within 5--16 years ([@bib5], [@bib6], [@bib7]). Longitudinal studies have shown that women with prior GDM and obesity were at higher risk to develop MetS compared with those without such metabolic history ([@bib8]), and these women with prior GDM and obesity had relatively higher values of anthropometric parameters (such as BMI and waist circumference), blood pressure, glucose, homeostatic model assessment, insulin, C-peptide and fibrinogen, together with lower HDL-C levels ([@bib9]).

Insulin resistance and central adiposity are of crucial importance in the development of MetS, and they appear to correlate with cardiovascular (CV) risk factors, including hypertension, atherogenic dyslipidaemia and glucose intolerance. The underlying mechanism of GDM is mainly pronounced insulin resistance ([@bib1]). However, other factors, such as race, ethnicity, environmental and genetic factors ([@bib10]), appear to contribute to the development of silent or clinical CV events. Interestingly, hypertensive disease of pregnancy (HDP) is very likely to be an accompanying co-morbidity in pregnancies complicated with GDM ([@bib11], [@bib12], [@bib13]). Indeed, both these gestational complications share common risk factors such as maternal age, parity and pre-pregnancy BMI. Arguably, they may also share underlying mechanisms predisposing to subsequent recurrence of pregnancy complications and postpartum cardiometabolic disorders ([@bib14], [@bib15], [@bib16], [@bib17], [@bib18]).

However, it may also be true that HDP and GDM are the result of inherent susceptibility to cardiovascular disease (CVD). Mothers who were obese or had a personal history of chronic hypertension or diabetes before pregnancy are more likely to develop HDP or GDM ([@bib19], [@bib20], [@bib21]), and family history of CV risk is closely related to future CVD ([@bib22], [@bib23]).

Is there a synergistic effect of GDM and HDP on postpartum cardiometabolic risk?
================================================================================

It has been reported that there is a significant link between pregnancy complications (GDM and HDP) and CVD later in life ([@bib18], [@bib24]), since HDP and GDM may promote endothelial inflammation and early atherosclerosis independently of underlying conditions ([@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30]). HDP and GDM also negatively impact on inflammatory biomarkers, including higher levels of plasminogen activator inhibitor-1, adiponectin, C-reactive protein, leptin and TNF alpha ([@bib1], [@bib14]). Importantly, these inflammatory biomarkers play an important role beyond their role in diabetes, insulin resistance, visceral obesity, CVD and hypertension ([@bib32], [@bib33]). Moreover, GDM and HDP are linked with elevated LDL-C and small dense LDL particles, which are implicated in CVD ([@bib31], [@bib34]).

Even though GDM and HDP may co-exist in pregnancies of the same mothers and are associated with CV risk, some controversy remains as to whether or not co-existent GDM and HDP have a synergistic effect to the risk of postpartum cardiometabolic disease ([@bib13]). GDM or HDP is associated with a 15-fold higher risk in postpartum diabetes, with a sixfold greater risk of postpartum hypertension and a 40% risk increase for CVD mortality in the mothers ([@bib35]). Meta-analyses have demonstrated that GDM is associated with a sevenfold higher risk of T2DM in affected mothers, and HDP is associated with a double risk of postpartum diabetes ([@bib5], [@bib26]). It has also been shown that a prior GDM can enhance the risk of having not only T2DM but also CVD, independently ([@bib36]).

Interestingly, the study of Li *et al*. ([@bib37]) shows that GMD and HDP contribute independently and not synergistically to the postpartum cardiometabolic risk, and this was somewhat unexpected, given the accumulating evidence ([@bib35], [@bib36], [@bib37]) that suggest that these conditions interplay in increasing the risk of diabetes, hypertension and CVD later in the mothers' lives as well as in their offspring ([@bib10], [@bib26], [@bib38]). There are some potential limitations in the study of Li *et al*. that need to be briefly discussed ([@bib37]). First, the small cohort of subjects and the relative brief follow-up period. In addition, GDM cases may be somewhat misclassified because the diabetes diagnosis required fasting and/or the 2-h glucose testing after a 75 g oral glucose intake. Further, the data on GDM and HDP history were based on self-reports only. Finally, as already highlighted by the authors, since some mothers with an episode of GDM and/or HDP did not or were not able to conceive, subsequently, these findings could have underestimated their risks.

It is well known in literature that women with GMD and HDP are more prone to MetS ([@bib39], [@bib40], [@bib41]), and they appear to transmit an increased risk to the offspring through vertical transmission ([@bib8]). Thus, it seems that women with GMD and HDP create an adverse metabolic memory ([@bib42]).

Conclusion
==========

Women who have had GDM and/or HDP are now recognised to carry a high risk of CVD and, regardless of the presence or absence of the synergism between GDM and HDP, they need to be followed very carefully. Indeed, the American Heart Association recommends long-term surveillance and management of CV risk factors in women with these pregnancy-related complications ([@bib43], [@bib44]). Of note, many women with GDM have later in life an undiagnosed T2DM ([@bib45]) and, therefore, increased awareness of GDM and HDP is needed. In addition, postpartum screening tools and biomarkers of subsequent risk are very helpful in long-termfollow-up.
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